124 related articles for article (PubMed ID: 38727085)
1. Clinical effectiveness of nirmatrelvir plus ritonavir on the short- and long-term outcome in high-risk children with COVID-19.
Wu JY; Chen CC; Liu MY; Hsu WH; Tsai YW; Liu TH; Pin-Chien S; Huang PY; Chuang MH; Lee MC; Hung KC; Yu T; Lai CC
J Med Virol; 2024 May; 96(5):e29662. PubMed ID: 38727085
[TBL] [Abstract][Full Text] [Related]
2. Association between nirmatrelvir plus ritonavir and the outcomes of non-hospitalized obese patients with COVID-19.
Wu JY; Liu MY; Liu TH; Chuang MH; Hsu WH; Huang PY; Tsai YW; Lai CC
Int J Antimicrob Agents; 2023 Dec; 62(6):106984. PubMed ID: 37769748
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of nirmatrelvir and ritonavir for post-acute COVID-19 sequelae beyond 3 months of SARS-CoV-2 infection.
Chuang MH; Wu JY; Liu TH; Hsu WH; Tsai YW; Huang PY; Lai CC
J Med Virol; 2023 Apr; 95(4):e28750. PubMed ID: 37185834
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of nirmatrelvir and ritonavir combination for treating diabetic patients with COVID-19.
Wu JY; Liu MY; Liu TH; Chuang MH; Hsu WH; Huang PY; Tsai YW; Kuo CY; Yeh CT; Lai CC
J Med Virol; 2023 Jun; 95(6):e28866. PubMed ID: 37314228
[TBL] [Abstract][Full Text] [Related]
5. Clinical effectiveness of oral antiviral agents in older patients with COVID-19 based on real-world data.
Tsai YW; Wu JY; Liu TH; Chuang MH; Hsu WH; Huang PY; Lai CC; Tsai KT; Shiue YL
J Med Virol; 2023 Jun; 95(6):e28869. PubMed ID: 37322616
[TBL] [Abstract][Full Text] [Related]
6. Clinical effectiveness of nirmatrelvir plus ritonavir in patients with COVID-19 and substance use disorders based on real-world data.
Liu TH; Huang PY; Wu JY; Chuang MH; Hsu WH; Tsai YW; Chang CC; Lai CC
J Med Virol; 2023 May; 95(5):e28801. PubMed ID: 37218308
[TBL] [Abstract][Full Text] [Related]
7. The effect of nirmatrelvir-ritonavir on the long-term risk of neuropsychiatric sequelae following COVID-19.
Liu TH; Wu JY; Huang PY; Tsai YW; Lai CC
J Med Virol; 2023 Jul; 95(7):e28951. PubMed ID: 37436873
[TBL] [Abstract][Full Text] [Related]
8. Clinical effectiveness of nirmatrelvir plus ritonavir in the treatment of COVID-19 in patients with cirrhosis.
Hsu WH; Shiau BW; Liu TH; Wu JY; Tsai YW; Huang PY; Chuang MH; Lai CC; Chen CH
Expert Rev Anti Infect Ther; 2023; 21(10):1143-1151. PubMed ID: 37795869
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of nirmatrelvir plus ritonavir in patients with COVID-19 and preexisting cardiovascular diseases.
Liu TH; Wu JY; Huang PY; Hsu WH; Chuang MH; Tsai YW; Lai CC; Huang CY
Expert Rev Anti Infect Ther; 2024; 22(1-3):121-128. PubMed ID: 37965890
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19-Related Hospitalization and Mortality: A Systematic Literature Review.
Cha-Silva AS; Gavaghan MB; Bergroth T; Alexander-Parrish R; Yang J; Draica F; Patel J; Garner DA; Stanford RH; Meier G; McLaughlin JM; Nguyen JL
Am J Ther; 2024 May-Jun 01; 31(3):e246-e257. PubMed ID: 38691664
[TBL] [Abstract][Full Text] [Related]
11. Clinical effectiveness of nirmatrelvir plus ritonavir for patients with COVID-19 and preexisting psychiatric disorders.
Liu TH; Wu JY; Huang PY; Hsu WH; Chuang MH; Tsai YW; Lai CC; Huang CL
Expert Rev Anti Infect Ther; 2024 May; ():1-9. PubMed ID: 38703086
[TBL] [Abstract][Full Text] [Related]
12. Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019.
Ganatra S; Dani SS; Ahmad J; Kumar A; Shah J; Abraham GM; McQuillen DP; Wachter RM; Sax PE
Clin Infect Dis; 2023 Feb; 76(4):563-572. PubMed ID: 35986628
[TBL] [Abstract][Full Text] [Related]
13. Nirmatrelvir/ritonavir or Molnupiravir for treatment of non-hospitalized patients with COVID-19 at risk of disease progression.
Butt AA; Yan P; Shaikh OS
PLoS One; 2024; 19(6):e0298254. PubMed ID: 38843201
[TBL] [Abstract][Full Text] [Related]
14. Oral Nirmatrelvir and Ritonavir for Coronavirus Disease 2019 in Vaccinated, Nonhospitalized Adults Aged 18-50 Years.
Faust JS; Kumar A; Shah J; Khadke S; Dani SS; Ganatra S; Sax PE
Clin Infect Dis; 2023 Nov; 77(9):1257-1264. PubMed ID: 37387690
[TBL] [Abstract][Full Text] [Related]
15. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225
[TBL] [Abstract][Full Text] [Related]
16. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of oral antiviral agents on long-term cardiovascular risk in nonhospitalized patients with COVID-19: A multicenter matched cohort study.
Liu TH; Chuang MH; Wu JY; Huang PY; Tsai YW; Hsu WH; Lai CC
J Med Virol; 2023 Aug; 95(8):e28992. PubMed ID: 37522355
[TBL] [Abstract][Full Text] [Related]
18. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
[TBL] [Abstract][Full Text] [Related]
19. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD015395. PubMed ID: 38032024
[TBL] [Abstract][Full Text] [Related]
20. Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment.
Lai CC; Hsueh PR
J Med Virol; 2023 Feb; 95(2):e28430. PubMed ID: 36571273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
